8 terminated. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Terminated 8 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines Ligelizumab, Placebo - Chronic Inducible Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 39 | 2021-11-16 | 2024-06-18 |
| A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Benralizumab, Placebo - Bullous Pemphigoid | Phase 3 | Terminated | AstraZeneca | 67 | 2021-03-31 | 2024-11-29 |
| Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab Ligelizumab - Chronic Spontaneous Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 1033 | 2020-04-08 | 2024-06-20 |
| Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema avoralstat - Hereditary Angioedema, HAE | Phase 3 | Terminated | BioCryst Pharmaceuticals | 6 | 2015-12-01 | 2016-02-17 |
| Chronic Urticaria - Long Term Assessment of Effects of Rupatadine 10 mg Rupatadine on demand, 10 mg Rupatadine, 20 mg Rupatadine - Chronic Urticaria | Phase 3 | Terminated | Charite University, Berlin, Germany | 192 | 2014-12-01 | 2019-09-17 |
| Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture C1-esterase inhibitor, Saline 0.9% - Trauma, Inflammation | Phase 3 | Terminated | UMC Utrecht | 11 | 2012-04-01 | 2015-02-04 |
| Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease Canakinumab - NOMID, CINCA Syndrome | Phase 3 | Terminated | Novartis Pharmaceuticals | 7 | 2009-01-26 | 2021-06-10 |
| Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria RUPATADINE - Urticaria | Phase 3 | Terminated | J. Uriach and Company | 300 | 2004-04-01 | 2005-12-23 |
Angioedemas, Hereditary (2) · Chronic Urticaria (2) · Pruritus (2) · Blister (1) · Chronic Inducible Urticaria (1) · Cold Urticaria (1) · Cryopyrin-Associated Periodic Syndromes (1) · Eosinophilia (1) · Familial dermographism (1) · Inflammation (1) · Multiple Organ Failure (1) · Pemphigoid, Bullous (1) · Rare Diseases (1) · Sepsis (1)
Hypersensitivity (8) · Hypersensitivity, Immediate (8) · Immune System Diseases (8) · Skin Diseases (8) · Skin Diseases, Vascular (8) · Skin and Connective Tissue Diseases (8) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (5) · Chronic Disease (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Angioedema (2) · Cardiovascular Diseases (2)
ligelizumab (2) · rupatadine (2) · Complement C1 Inhibitor Protein (1) · Sodium Chloride (1) · avoralstat (1) · benralizumab (1) · canakinumab (1)
Novartis Pharmaceuticals (3) · AstraZeneca (1) · BioCryst Pharmaceuticals (1) · Charite University, Berlin, Germany (1) · J. Uriach and Company (1) · UMC Utrecht (1)
United States (4) · Australia (3) · France (3) · Germany (3) · Greece (3) · Spain (3) · Belgium (2) · Bulgaria (2) · Hungary (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2) · Russia (2) · Slovakia (2)
Henriette Farkas, MD, PhD, DSc (1) · Luke P Leenen, MD, PhD (1)
2019 (1), 2023 (1)